Comparative Effectiveness of Anti-Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta-Analysis

Table 1

Characteristics of included studies.

Trials	Study design	Year of study	No. of patients	Study population	Lost to F/U	Age	Female %	Smoking history	DM	HTN	HLD	Prior ACS/MI	Prior CHF	Prior PCI	Prior CABG	CRP (mg/L)	IL-6 (mg/L)
APEX AMI [28]	RCT	2007	2860 (T)	STEMI (100)	6 (0.2)	61 (51-71)	691 (24.2)	1226 (42.9)	446 (15.6)			340 (11.9)	105 (3.7)	278 (9.7)	60 (2.1)
			2885 (P)	STEMI (100)	9 (0.3)	61 (52-71)	634 (22.0)	1252 (43.6)	467 (16.2)			354 (12.3)	103 (3.6)	284 (9.9)	68 (2.4)
COMMA [16]	RCT	2003	262 (T)	STEMI (100)	3 (1.1)	58 (50 to 72)	24%	37%	20%	64%		16%	9%
			242 (P)	STEMI (100)	4 (1.7)	61 (51 to 70)	24%	40%	21%	61%		17%	9%
COMPLY [16]	RCT	2003	309 (T)	STEMI (100)	0	62 (52 to 70)	28%	40%	14%	59%		22%	13%
			307 (P)	STEMI (100)	1 (0.3)	60 (52 to 70)	33%	42%	16%	56%		17%	8.50%
PRIMO CABG [32]	RCT	2006	1553 (T)	CABG w/wo concurrent valve surgery (100)	7	65.1 (10.2)	440 (28.3)		376 (24.2)	1103 (71.0)		599 (38.6)	245 (15.8)	101 (6.5)	133 (8.6)
			1546 (P)	CABG w/wo concurrent valve surgery (100)	10	65.3 (10.3)	391 (25.3)		373 (24.1)	1104 (71.4)		624 (40.4)	219 (14.2)	109 (7.1)	128 (8.3)
PRIMO CABG II [31]	RCT	2010	2142 (T)	CABG w/wo concurrent valve surgery (100)	18 (0.8)	66.2 (31–91)	839 (39.2)		1298 (60.6)				838 (39.1)		228 (10.6)
			2112 (P)	CABG w/wo concurrent valve surgery (100)	19 (0.9)	66.2 (35–90)	852 (40.3)		1246 (59.0)				843 (40.0)		199 (9.4)
Pexelizumab study investigators [30]	RCT	2004	300 (T)	CABG w/wo concurrent valve surgery (100)	NA
			306 (P)	CABG w/wo concurrent valve surgery (100)	NA
MRC-ILA Heart Study [35]	RCT	2015	98 (T)	NSTEMI (100)	2(2.0)	61.4 (11.7)	35 (32.3)	34 (36.6)	15 (15)	31 (33.3)	27 (29.0)	23 (24.7)				5.38 (4.12, 7.04)	6.01 (4.68, 7.72)
			89 (P)	NSTEMI (100)	0	61.3 (12.3)	22(34.7)	31 (34.8)	8 (9)	29 (32.6)	28 (31.5)	24 (27.0)				5.21 (3.75, 7.22)	5.23 (3.98, 6.88)
VCU-ART 1&2 [33]	RCT	2015	20 (T)	STEMI (100)	0	57 (48-60)	8 (40)	12 (60)	5 (25)	12 (60)	14 (70)
			20 (P)	STEMI (100)	0	58 (51-65)	2 (10)	14 (70)	4 (20)	14 (70)	13 (65)
VCU-ART 3 [34]	RCT	2020	33 (T)	STEMI (100)	0	53 (49-62)	9 (27)		6 (18)	13 (39)
			35 (P)	STEMI (100)	0	56 (51-65)	5 (14)		15 (43)	23 (66)
LODOCO [36]	RCT	2010	282 (T)	Stable Coronary Heart Disease (100)	0		31 (11)	10 (4)	92 (33)			64 (23)		169 (60)	62 (22)
			250 (P)	Stable Coronary Heart Disease (100)	0		28 (11)	14 (6)	69 (28)			61 (24)		138 (55)	39 (16)
COLCOT [37]	RCT	2019	2366 (T)	STEMI (NA), NSTEMI (NA)	39 (1.6)		472 (19.9)	708/2366 (29.9)	462 (19.5)	1185 (50.1)		370 (15.6)	48 (2.0)	392 (16.6)	69 (2.9)
			2379 (P)	STEMI (NA), NSTEMI (NA)	50 (2.1)		437 (18.4)	708/2377 (29.8)	497 (20.9)	1236 (52.0)		397 (16.7)	42 (1.8)	406 (17.1)	81 (3.4)
SOLID TIMI 52 [38]	RCT	2014	6504 (T)	STEMI (46.1), NSTEMI (41.6) and UA (12.2)	43 (0.7)	64 (59-70)	1657 (25.5)	1227/6501 (18.9)	2275 (35.0)	4793 (73.7)	4191 (64.5)	2013 (31.0)		1532 (23.6)
			6522 (P)	STEMI (44.2), NSTEMI (43.7), UA (12.1)	41 (0.6)	64 (59-71)	1669 (25.6)	1245/6513 (19.1)	2227 (34.1)	4762 (73.0)	4165 (63.9)	2033 (31.2)		1580 (24.2)
STABILITY [39]	RCT	2014	7924 (T)	Stable Coronary Heart Disease (100)	80 (1.0)	65.0 (59.0–71.0)	1461 (18.4)	1572 (19.8)	2664 (33.6)			4681 (59.1)		3987 (50.3)	2644 (33.4)
			7904 (P)	Stable Coronary Heart Disease (100)	69 (0.9)	65.0 (59.0–71.0)	1506 (19.1)	1656 (21.0)	2687 (34.0)			4642 (58.7)		3978 (50.3)	2592 (32.8)
FRANCIS [41]	RCT	2010	313 (T)	STEMI (42.2), NSTEMI (36.4), UA (21.4)	6 (1.9)		26.5	73 (23.3)	84 (26.8)	271 (86.6)	120 (38.3)			97 (31.0)		12.0 (0–222)	5.22 (2.79–12.10)
			311 (P)	STEMI (40.8), NSTEMI (33.4), UA (25.7)	3 (1.0)		24.1	68 (21.9)	87 (28.0)	274 (88.1)	109 (35.0)			66 (21.2)		9.9 (0–377)	5.16 (2.69–10.94)
VISTA-16 [40]	RCT	2014	2572 (T)	STEMI (47.4), NSTEMI (37.4), UA (15.3)	26 (1.0)	61.0 (10.0)	691 (26.9)	854 (33.4)	801 (31.3)	1911 (75.2)	1255 (49.3)	769 (30.2)		453 (17.7)	161 (6.3)	11.4 (4.5-33.0)
			2573 (P)	STEMI (46.9), NSTEMI (38.0), UA (15.1)	32 (1.2)	60.7 (9.8)	660 (25.7)	860 (33.6)	803 (31.3)	1977 (77.8)	1292 (50.9)	743 (29.6)		476 (18.6)	182 (7.1)	10.4 (4.0-28.7)
CANTOS [17]	RCT	2017	2263 (T)	STEMI (53.6), NSTEMI (33.6), unknown type of missing data (12.8)	4 (0.2)		606 (26.8)	536 (23.7)	888 (39.2)	1799 (79.5)			523 (23.1)	1509 (66.7)	316 (14)	4.15 (2.85-7.15)	2.59 (1.79-4.08)
			3344 (P)	STEMI (54.0), NSTEMI (33.9), unknown type of missing data (12.1)	9 (0.3)		865 (25.9)	765 (22.9)	1333 (39.9)	2644 (79.1)			721 (21.6)	2192 (65.6)	469 (14)	41.1 (2.75-6.85)	2.61 (1.8-4.06)
SELECT-CABG [42]	RCT	2016	148 (T)	CABG (100)	NA		16(10.8)
			144 (P)	CABG (100)	NA		15(10.4)
LATITUDE TIMI-60 [43]	RCT	2016	1731 (T)	STEMI (25.0), NSTEMI (75.0)	NA	66 (61-74)	500 (28.9)	464 (26.8)	582 (33.6)	1268 (73.3)	985 (56.9)	425 (24.6)	206 (11.9)	412 (23.8)	154 (8.9)	3.6 (1.7-9.6)
			1758 (P)	STEMI (24.6), NSTEMI (75.4)	NA	67 (61-73)	532 (30.3)	449 (25.6)	586 (33.3)	1276 (72.6)	936 (53.2)	426 (24.2)	216 (12.3)	410 (23.3)	137 (7.8)	3.7 (1.7-9.9)
SOLSTICE ^3	RCT	2012	192 (T)	NSTEMI (100)	3	63 (57–73)	57 (30)	56 (29)	59 (31)	136 (71)	115 (60)	46 (24)	16 (8)	55 (29)	21 (11)	37.1 (16.2-83.8)	5.3 (2.9-8.6)
			135 (P)	NSTEMI (100)	0	64 (56–71)	40 (30)	46 (34)	37 (27)	97 (72)	74 (55)	33 (17)	6 (4)	21 (16)	11 (8)	33.3 (13.3-102.9)	4.8 (2.8-9.8)

Studies with subgroup analysis. denotes mean (SD); otherwise, they are number (percentage). Range values are median (interquartile range). SD: standard deviation; NA: not available; T: treatment group; P: placebo group.